Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Neurocognitive Disorder
  • Track 1-2Types of dementia
  • Track 1-3Prevalence of Dementia In Ireland
  • Track 1-4Need for awareness on dementia
  • Track 2-1Alzheimer's disease pathophysiology and mechanisms
  • Track 2-2Genetics in Alzheimer's disease
  • Track 2-3Risk factors: head injury, depression and hypertention
  • Track 2-4Causes and preventions in Alzheimer's disease
  • Track 2-5Medication and diet for Alzheimer's disease
  • Track 2-6Symptoms of Alzheimer's disease
  • Track 2-7Brain imaging for Alzheimer's disease
  • Track 2-8Treatments in Alzheimer's
  • Track 2-9Cholinergic and amloid hypothesis in Alzheimer's
  • Track 2-10Alzheimer's disease associated complexities
  • Track 2-11Clinical Trials for Alzheimer's Disease
  • Track 2-12Recent advancements in Alzheimer's disease
  • Track 2-13Latest tests for detection of Alzheimer's disease
  • Track 3-1Vascular dementia treatment and management
  • Track 3-2Vascular dementia prevalence
  • Track 3-3Pathology of vascular dementia
  • Track 3-4Risk factors in vascular dementia
  • Track 3-5Strokes in vascular dementia
  • Track 3-6Subcortical vascular dementia
  • Track 3-7Stratagies for vascular dementia caregivers
  • Track 3-8Emerging therapies for vascular dementia
  • Track 4-1Stages of Lewy body dementia
  • Track 4-2Alpha- synuclein protein associated with Lewy body dementia
  • Track 4-3Lewy body dementia and Parkinson's disease
  • Track 4-4Physiotherapy affects in Lewy body dementia
  • Track 4-5Advancement in treatment of Lewy body dementia
  • Track 4-6Latest Lewy body dementia research
  • Track 5-1Frontotemporal dementia signs and diagnosis
  • Track 5-2Management of frontotemporal dementia
  • Track 5-3Spindle neurons
  • Track 5-4Primary progressive aphasia
  • Track 5-5Semantic dementia
  • Track 5-6Neuropsychological tests for frontotemporal dementia
  • Track 5-7Frontotemporal dementia and life expectancy
  • Track 6-1Medication in mixed dementia
  • Track 6-2Treatments for mixed dementia
  • Track 6-3Management of mixed dementia
  • Track 6-4Alzheimer's , Vascular and Lwey body dementia coexistance
  • Track 6-5Sleep and mixed dementia
  • Track 6-6Current research on Mixed Dementia
  • Track 7-1Early stage dementia
  • Track 7-2Mid stage dementia
  • Track 7-3Late stage dementia
  • Track 7-4Mild cognitive impairement
  • Track 7-5Cognitive memory loss
  • Track 7-6Speech Impairment
  • Track 7-7Loss of physcomotor skills
  • Track 8-1Characteristics of reversible dementia
  • Track 8-2Causes of reversible dementia
  • Track 8-3Depression
  • Track 8-4Adverse effect of drugs
  • Track 8-5Normal pressure hydrocephalus
  • Track 8-6Central nervous system infections
  • Track 8-7Alcohol abuse
  • Track 9-1Measuring proteins in blood
  • Track 9-2Mini mental state examination
  • Track 9-3Mental score test
  • Track 9-4Trail making test
  • Track 9-5Clock drawing test
  • Track 9-6Geriatric depression scale
  • Track 9-7Brain MRI scan
  • Track 9-8People with memory problems
  • Track 9-9Biomarkers for diagnosis
  • Track 10-1Age: factor for dementia related diseases
  • Track 10-2Mental illness
  • Track 10-3Hypertention
  • Track 10-4Genetics in Dementia
  • Track 10-5Hypothryroidism
  • Track 10-6Vitamin B12 deficiency
  • Track 10-7Neurosyphillis
  • Track 10-8Beta Amloid Accumulation
  • Track 10-9Perception and visual problems
  • Track 10-10Traumatic brain injury
  • Track 10-11Down syndrome
  • Track 10-12Mild cognitive impairment
  • Track 11-1End of life care
  • Track 11-2Ensuring safety and security of dementia patients
  • Track 11-3Exercise promoting mobility and special diet for dementia patients
  • Track 11-4Visial and acoustic stimulation
  • Track 11-5Communication affects over dementia patients
  • Track 11-6Emergency preparedness
  • Track 11-7Social enguagement
  • Track 11-8Art therapy- quality of life
  • Track 11-9Telecare
  • Track 12-1Public awarness
  • Track 12-2Social policy
  • Track 12-3National and local awareness activities
  • Track 12-4Health and social system developments
  • Track 12-5Support for informal care and caregivers
  • Track 13-1Person living with dementia
  • Track 13-2History of present illness in dementia patients
  • Track 13-3Coping with caring
  • Track 13-4HIV associated dementia case report
  • Track 13-5Vocalisation in dementia
  • Track 13-6Nonconvulsive seizures and dementia
  • Track 14-1Vaccine against beta-amloid
  • Track 14-2Beta-amloid polymerisation and inflammation inhibitor
  • Track 14-3Aggregation of Tau inhibition
  • Track 14-4Prevention trials
  • Track 14-5Advances in genetic research
  • Track 15-1Cholinesterase inhibitors
  • Track 15-2Memantine
  • Track 15-3Medication for memory loss
  • Track 15-4Beta and gamma secretase inhibitors
  • Track 15-5Vitamin E and Omega-3-fatty acids
  • Track 15-6New drug development in dementia
  • Track 16-1Transgenic mice model
  • Track 16-2Rodent models
  • Track 16-3Transgenic and gene targeted models in dementia
  • Track 16-4Pharmacological validation in animal model of dementia
  • Track 16-5Validation of dementia models employing neuroimaging techniques
  • Track 16-6Drosophila melanogaster as a model organism for dementia
  • Track 16-7Zebrafish as a model organism for dementia
  • Track 16-8Lesion-induced vertebrate models of Alzheimer's dementia
  • Track 16-9AΒ infusion and related models of Alzheimer's dementia
  • Track 16-10APP-based transgenic models
  • Track 17-1Reminiscence therapy
  • Track 17-2Psychological therapies
  • Track 17-3Dementia care advances through cloud technology
  • Track 17-4Natural treatments in dementia
  • Track 17-5Advances in person centred care in dementia
  • Track 17-6Home care thrapies